联合缬沙坦用药治疗乙型肝炎肝纤维化的成本—效果分析

Cost-effectiveness Analysis of Combined Valsartan Medication in the Treatment of Chronic Hepatitis B Fibrosis

目的:评价两种治疗慢性乙型肝炎肝纤维化方案的成本-效果。方法:90例乙型肝炎肝纤维化患者随机分为恩替卡韦加复方鳖甲软肝组(A组)和恩替卡韦加复方鳖甲软肝片联合缬沙坦组(B组),疗程6个月。分别在治疗前后检测两组患者的肝纤维化指标、瞬时弹性成像,计算有效率,比较两种方案的成本-效果。结果:A组成本为9232.50元,有效率为78.26%,成本-效果比为11797;B组成本为9527.70元,有效率为86.36%,成本-效果比为11031,B组方案具有较好的成本-效果。结论:恩替卡韦加复方鳖甲软肝联合缬沙坦组治疗慢性乙肝肝纤维化优于恩替卡韦加复方鳖甲软肝片组。

Objective： To analyze the cost-effectiveness of two medication schemes in the treatment of chronic hepatitis B fibrosis. Methods： 90 cases of chronic hepatitis B fibrosis were randomly divided into entecavir Fufang Biejia Ruangan tablets group（group A, n=46） and entecavir Fufang Biejia Ruangan tablets combined with Valsartan group（group B, n=34）. The liver fibrosis index and transient elastography of 2 groups were detected before and after 6-month-treatment, and effective rate was calculated to compare the cost-effectiveness of the 2 groups. Results： The cost, effective rate and cost-effectiveness ratio of group A were 9232.50 yuan, 78.26% and 11797 respectively; those of group B were 9527.70 yuan, 86.36% and 11031 respectively; indicating group B had better cost-effectiveness. Conclusion： The cost-effectiveness of entecavir and Fufang Biejia Ruangan tablets combined with Valsartan is better than that of entecavir and Fufang Biejia Ruangan tablets in the treatment of chronic hepatitis B fibrosis.